Area of research
Pulmonary and Respiratory Medicine · Rheumatology
Research interest
Research interests include Medicine, Osteosarcoma, Oncology, Chemotherapy, Rhabdomyosarcoma, and Internal medicine.
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumors of childhood and adolescence
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee.
Anaplastic rhabdomyosarcoma in <i>TP53</i> germline mutation carriers
Mutations in Hedgehog pathway genes in fetal rhabdomyomas
MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.
MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.
Discordance of oncologic surgical classifications in COG studies.
EURAMOS-1 study: Recruitment, characteristics, and initial treatment of more than 2,000 patients (pts) with high-grade osteosarcoma.